Corporate Banner
Satellite Banner
qPCR
Scientific Community
 
Become a Member | Sign in
Home
  
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Analysing 10,000 Cells Simultaneously
New techniquethat traps 10,000 cells on a single chip has potential for cancer screening for individuals.
$1M NIH Grant to Refine PCR Based Cancer Test
Researchers at Cornell University, Weill Cornell Medicine, the University of California, San Francisco, and the Infectious Diseases Institute in Kampala, Uganda, recieve a four-year, $1 million grant to hone technology for a quick, in-the-field diagnosis of Kaposi's sarcoma — a cancer frequently related to HIV infections.
Genetic Tug of War Before Cells Decide Fate
Researchers report that as developing blood cells are triggered by genetic signals firing on and off, a 'tug of war' occurs.
Linkage Biosciences Awarded NHS Contract
Comapny announces that it has been awarded a four-year contract by NHS Blood and Transplant (NHSBT) in the UK for implementation of the LinkSeq™ Real-Time PCR HLA typing product.
Understanding Tumor Evolution
Study provides insight into tumor evolution; may point to improved diagnosis and treatment.
Frankfurter Fraud: Finding Out What’s In Your Hot Dog
Scientists have developed a technique to test the meat content of Frankfurters.
How Cloud Connectivity Can Combat the Reproducibility Crisis
This infographic explains the reproducibility crisis, and how cloud connectivity can help overcome this problem.
Keeping Cells in Shape to Fight Sepsis
Boosting levels of a protein that controls the shape and activity of a crucial group of white blood cells improves survival and recovery chances during sepsis.
This 3D Printer Can Detect Infectious Diseases
Researchers at AI Biosciences, Inc. have repurposed 3D printers into machines capable of performing sample preparation and DNA amplification.

Biomarkers in Late-Stage Clinical Trials: Applications, opportunities and activities of leading players
Bookmark and Share

Biomarkers reduce the attrition rate of late-stage clinical trials by assessing drug potential in terms of efficacy and toxicity at the early stages of clinical development. Thus, biomarkers significantly increase productivity, lower the cost and duration of clinical trials, and help researchers complete the drug development process at a faster pace.

Scope of this research

  • Assessment of the revenues of late-stage biomarker technology and services in North America, Europe, Asia and the rest of the world.
  • Details of the key market drivers and restraints in the biomarker sector.
  • Information about microarrays, immunoassay, LC/MS and GC/MS, flow cytometry, imaging, PCR and services.
  • Patent analysis with respect to competitors and geography.
  • Discussion of major pharmaceutical companies, biotechs, contract research organizations and biomarker specialists.

Research and analysis highlights

The pharmaceutical and biotech sectors are currently facing increasing duration and cost issues related to clinical trials in drug discovery. Funding from government sources such as the National Institutes of Health has not increased significantly over the last few years.

More than 50% of clinical trials fail in Phase III for a host of reasons, including greater disease complexity, stiffer clinical endpoints, and the inability of the data to prove drug effectiveness.

Biomarkers play a crucial role in late-stage clinical trials by acting as surrogate endpoints for patient monitoring and stratification. Surrogate endpoints help measure treatment efficacy, and thus facilitate significant cost reductions in the drug development process.

Key reasons to purchase this research

  • Examine and evaluate the growth potential of emerging technologies.
  • Understand biomarker activity in the clinical trials of leading market players.
  • Gain knowledge about the relative importance of biomarker late-stage clinical trials technologies over the next five years.
  • Determine the collaborations and partnerships of the major market players.




SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!